Board Changes Ahead of Corporate Growth
Key Highlights
-
Experienced pharma executive, Dr Beata Niechoda, joins Noxopharm Board
-
Mr John Moore becomes Executive Chairman of Noxopharm spin-off, Nyrada
-
Nyrada Board expanded with the addition of 2 international directors
SYDNEY, 16 July 2019: Following the recent move of Graham Kelly from CEO to Executive Chairman, Noxopharm Ltd (‘Noxopharm’) (ASX:NOX) is pleased to announce a series of further planned changes in Board membership for both itself and its subsidiary company, Nyrada Inc. (‘Nyrada’). The changes reflect the considerable progress being made in the businesses of both companies, their growing independence from each other, and plans for future listings on security exchanges.
For further information please download the attached PDF:
Download this document
